Pelthos Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(7,955,338) | $(7,380,793) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization of debt discount | 692,020 | 188,119 |
| Issuance cost from shares issued on extension of investor note | — | 201,600 |
| Stock-based compensation | 1,799,295 | 1,733,233 |
| Shares issued for license | — | 2,225,733 |
| Gain on default judgement | (363,091) | — |
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued expenses | 1,178,573 | 1,627,005 |
| Accrued compensation | (282,856) | 424,072 |
| Due from Chromocell Corporation | (45,786) | — |
| Prepaid expenses | (65,300) | — |
| Deferred offering costs | (750,000) | — |
| Net Cash Used In Operating Activities | (5,792,483) | (981,031) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from loan payable, net of debt discount | 536,184 | 201,008 |
| Proceeds from loan payable - related party, net of debt discount | — | 565,928 |
| Payment of bridge loan, net of debt discount | (214,757) | — |
| Common stock issued for cash | 5,972,000 | 255,412 |
| Recission of common stock | (91,512) | — |
| Repurchase of Common Stock under Stock Repurchase Plan | (75,000) | — |
| Shares issued for cash under equity line of credit | 82,620 | — |
| Net Cash Provided By Financing Activities | 6,209,535 | 1,022,348 |
| NET INCREASE IN CASH | 417,052 | 41,317 |
| CASH AT BEGINNING OF YEAR | 96,391 | 55,074 |
| CASH AT END OF YEAR | $513,443 | $96,391 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $— | $— |
| Cash paid for interest expense | $— | $— |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Shares forfeited | $ | $13 |
| Debt discount from common stock issued for extension of bridge loan | $447,779 | $428,400 |
| Conversion of notes to common stock | $1,362,821 | $— |
| Transfer of liabilities to Chromocell Corp for Series C Preferred Stock | $2,153,362 | $— |
| Accounts payable and accrued expenses converted to loans payable | $1,455,416 | $— |
| Accounts payable and accrued expenses converted to loans payable - related party | $131,868 | $— |
| Shares issued for payment of accounts payable | $7,339 | $— |
| Shares issued for payment of accrued interest | $3,344 | $— |
| Shares issued for payment of principal on loan payable | $23,788 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.